1. Home
  2. BMR vs XLO Comparison

BMR vs XLO Comparison

Compare BMR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beamr Imaging Ltd.

BMR

Beamr Imaging Ltd.

HOLD

Current Price

$1.97

Market Cap

47.4M

Sector

Technology

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMR
XLO
Founded
2009
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.4M
41.8M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
BMR
XLO
Price
$1.97
$0.65
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$2.00
AVG Volume (30 Days)
87.6K
563.4K
Earning Date
08-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,131,000.00
$31,804,000.00
Revenue This Year
$21.21
$589.60
Revenue Next Year
N/A
$38.00
P/E Ratio
N/A
N/A
Revenue Growth
5.96
588.40
52 Week Low
$1.86
$0.62
52 Week High
$6.59
$1.70

Technical Indicators

Market Signals
Indicator
BMR
XLO
Relative Strength Index (RSI) 37.57 32.76
Support Level $2.18 $0.64
Resistance Level $2.21 $0.73
Average True Range (ATR) 0.17 0.04
MACD -0.02 -0.01
Stochastic Oscillator 8.08 15.89

Price Performance

Historical Comparison
BMR
XLO

About BMR Beamr Imaging Ltd.

Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: